CC-10004 For The Treatment Of Vulvodynia

Status Completed

Clinical Trial Summary

Vulvodynia is characterized by persistent vulvar pain, which often occurs upon touch or pressure. The cause of vulvodynia is unknown but is presumed to involve many factors. Some of these factors may include altered immune response, infections, altered vaginal acid-base balance, allergic reactions and psychosexual disorders. Women are generally treated with medications such as anti-histamines, anti-depressants and anti-inflammatories, or with physical therapy to minimize symptoms. Other therapies for vulvodynia include topical agents (lidocaine, or compounded medications such as baclofen, gabapentin and amitriptyline), oral medications (gabapentin, pregabalin, calcium citrate), complementary therapies (yoga, guided imagery, cognitive behavioral therapy) or a low-oxalate diet, but these are often ineffective. Surgery for vulvodynia may be helpful in the hard to manage cases, but is utilized as a last resort.

Clinical Trial Description

CC-10004 is a well-tolerated, selective PDE4 inhibitor with a demonstrated inhibitory effect on inflammatory mediators and is under development for the treatment of inflammatory and immune mediated conditions.

This is an open-label, one arm, phase II study at William Beaumont Hospital. Twenty female subjects aged 18 or older meeting criteria for diagnosis of vulvodynia or vulvar vestibulitis (vestibulodynia) will be treated with CC-10004 at 20mg orally twice a day for 12 weeks.The patient will be seen for a total of ten visits by the study coordinator. ;

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Vulvodynia

Clinical Trial Details

NCT number	NCT00814632
Study type	Interventional
Source	William Beaumont Hospitals
Contact
Status	Completed
Phase	Phase 2
Start date	December 2008
Completion date	February 2011

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT05478746` - Effects of Flourish HEC on Localized Provoked Vulvodynia	N/A
Completed	`NCT02404961` - Women's Health Study: Immunological Factors and Risk of Vulvodynia
Completed	`NCT00751010` - Relationship: Interstitial Cystitis & Vulvodynia-Part 2	N/A
Completed	`NCT00607490` - A Randomized Clinical Trial for Women With Vulvodynia	N/A
Recruiting	`NCT03640624` - Multidisciplinary Treatment of Chronic Vulvar Pain	N/A
Recruiting	`NCT05343182` - Vestibulectomy Surgical Techniques Comparison Study	N/A
Recruiting	`NCT05518630` - An Investigation of Nomothetic Versus Idiographic Assessment in Chronic Pain
Recruiting	`NCT05597358` - Efficacy of High Intensity Laser for Provoked Vestibulodynia	N/A
Completed	`NCT01304589` - Savella in Treatment for Provoked Vestibulodynia	Phase 3
Completed	`NCT00590590` - Safety and Efficacy of Two Vaginal Products Versus Placebo in Patients With Vaginal Discomfort	Phase 2
Recruiting	`NCT06138171` - Personality, Defences, Central Sensitization, and Trauma in Women With Chronic Migraine, Fibromyalgia, and Vulvodynia
Completed	`NCT01996384` - Provoked, Localized Vulvodynia Treatment With Acupuncture and Lidocaine Pilot Study	Phase 1
Completed	`NCT01664962` - Search for Genetic Basis of Vulvodynia	N/A
Recruiting	`NCT05955313` - Effectiveness of Low-dose Naltrexone in Patients With Different Types of Vulvodynia	Phase 2
Completed	`NCT02773641` - Placebo-controlled RCT of Botulinum Toxin A as a Treatment for Provoked Vestibulodynia	Phase 3
Completed	`NCT00501774` - A Search for Helicobacter Pylori in Localized Vulvodynia	N/A
Completed	`NCT04057755` - Botulinum Toxin A as a Treatment for Provoked Vestibulodynia	Phase 3
Terminated	`NCT04016467` - Effect of Spinal Manipulation on Vulvar Pain	N/A
Completed	`NCT01935063` - Study to Compare the Efficacy of Cognitive-behavioral Couple Therapy and Lidocaine for Provoked Vestibulodynia	N/A
Completed	`NCT02809612` - An Internet-based Information Platform for Vulvodynia Patients	N/A